This is a randomized, open-label, multicenter, parallel-groups study of multiple intravenous doses of Puricase, administered intravenously, in 40 patients with symptomatic gout. Subjects must wash out of any uric acid-lowering agents for one week before being dosed, and must refrain from using such agents throughout the study.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
40
Spain Rehabilitation Center
Birmingham, Alabama, United States
University of California, San Diego
La Jolla, California, United States
University of Chicago Dept of Medicine
Chicago, Illinois, United States
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Graves Gilbert Clinic
Bowling Green, Kentucky, United States
Center for Rheumatology and Bone Research
Wheaton, Maryland, United States
North Shore University Hospital Division of Rheumatology
Manhasset, New York, United States
Duke University Medical Center
Durham, North Carolina, United States
Oregon Health & Science University Arthritis & Rheumatic Diseases
Portland, Oregon, United States
Pride Clinical research Associates
Pittsburgh, Pennsylvania, United States